Evidence map›Paper›PMID 28655134›Full record

ReviewJournal of Alzheimer's disease : JAD2017

Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer's Disease: Testosterone as a Modifier.

Prita R Asih, Michelle L Tegg, Hamid Sohrabi, Malcolm Carruthers, Samuel E Gandy, Farid Saad, Giuseppe Verdile, Lars M Ittner, Ralph N Martins

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Correlation Between Serum Vitamin E and HOMA-IR in Patients with T2DM.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  6. Article
  7. Testosterone, cognitive decline and dementia in ageing men.Reviews in endocrine & metabolic disorders · 2022
    Review
  8. Impact of Testosterone on Alzheimer's Disease.The world journal of men's health · 2022
    Review
  9. Article
  10. Article
  11. Nutrients · 2021
    Article
  12. Caveolin: A New Link Between Diabetes and AD.Cellular and molecular neurobiology · 2020
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Prita R AsihDepartment of Anatomy, Dementia Research Unit, School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Michelle L TeggSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Hamid SohrabiSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Malcolm CarruthersCentre for Men's Health, London, UK.
Samuel E GandyDepartments of Neurology and Psychiatry and the Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY, USA.
Farid SaadBayer Pharma AG, Global Medical Affairs Andrology, Berlin, Germany.
Giuseppe VerdileAustralian Alzheimer's Research Foundation Perth, WA, Australia.
Lars M IttnerDepartment of Anatomy, Dementia Research Unit, School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Ralph N MartinsKaRa Institute of Neurological Diseases, Sydney, NSW, Australia.
UNSW Sydney · AUAustralian Alzheimer’s Research Foundation · AUBayer (Germany) · DEEdith Cowan University · AUIcahn School of Medicine at Mount Sinai · USMacquarie University · AUMen's Health Forum · GBUniversity of Western Australia · AU

Funding

VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
NIA NIH HHS P50 AG005138
6 · The paper itself

Abstract

Evidence in support of links between type-2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) has increased considerably in recent years. AD pathological hallmarks include the accumulation of extracellular amyloid-β (Aβ) and intracellular hyperphosphorylated tau in the brain, which are hypothesized to promote inflammation, oxidative stress, and neuronal loss. T2DM exhibits many AD pathological features, including reduced brain insulin uptake, lipid dysregulation, inflammation, oxidative stress, and depression; T2DM has also been shown to increase AD risk, and with increasing age, the prevalence of both conditions increases. In addition, amylin deposition in the pancreas is more common in AD than in normal aging, and although there is no significant increase in cerebral Aβ deposition in T2DM, the extent of Aβ accumulation in AD correlates with T2DM duration. Given these similarities and correlations, there may be common underlying mechanism(s) that predispose to both T2DM and AD. In other studies, an age-related gradual loss of testosterone and an increase in testosterone resistance has been shown in men; low testosterone levels can also occur in women. In this review, we focus on the evidence for low testosterone levels contributing to an increased risk of T2DM and AD, and the potential of testosterone treatment in reducing this risk in both men and women. However, such testosterone treatment may need to be long-term, and would need regular monitoring to maintain testosterone at physiological levels. It is possible that a combination of testosterone therapy together with a healthy lifestyle approach, including improved diet and exercise, may significantly reduce AD risk.

Indexed as

Alzheimer DiseaseDiabetes Mellitus, Type 2AnimalsBrainHumansTestosteroneTestosteroneAlzheimer’s diseasementestosteronetype-2 diabeteswomen

Identifiers

PMID28655134
PMCPMC6462402
OpenAlexW2704863468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.